Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to seven new employees as employment inducement awards. The options total 204,163 shares with an exercise price of $2.73 per share, matching the closing price on September 30, 2025.

The options feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia. The grants were made under Nasdaq Listing Rule 5635(c)(4).

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 204,163 shares of Akebia’s common stock on September 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.73 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

FAQ

What stock options did Akebia Therapeutics (AKBA) grant to new employees in September 2025?

Akebia granted options to purchase 204,163 shares to seven new employees at an exercise price of $2.73 per share.

What is the vesting schedule for Akebia Therapeutics' (AKBA) September 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, subject to continued employment.

What is the exercise price for Akebia Therapeutics' (AKBA) September 2025 inducement grants?

The exercise price is $2.73 per share, equal to AKBA's closing price on September 30, 2025.

How long is the term of Akebia Therapeutics' (AKBA) September 2025 employee stock options?

Each stock option has a 10-year term and is subject to Akebia's inducement award program terms and conditions.